ArticleThe Journal of allergy and clinical immunology2025
Massively parallel analysis of genotype-dependent enhancer activity among atopic dermatitis genetic risk variants.
Article in The Journal of allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-genome-wide association study variant-to-function challenges in asthma research.The Journal of allergy and clinical immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundAtopic dermatitis (AD) is an inflammatory, pruritic disease of the skin with a complex etiology involving environmental and genetic factors. Numerous genetic risk loci for AD have been nominated through genome-wide association studies, with most associated variants residing in noncoding regions. Further work is needed to understand how genetic variation contributes to disease-related alterations to gene expression.
objectiveWe sought to use massively parallel reporter assays to identify genetic risk variants with genotype-dependent regulatory activity within a set of 2,381 variants distributed among 49 independent AD risk loci.
methodsWe used our massively parallel reporter assay library in HaCaT skin keratinocytes, TE-7 esophageal epithelial cells, and Jurkat T cells, enabling the identification of shared and cell-type-specific variants with genotype-dependent enhancer activity. Stimulation of HaCaT and TE-7 cells with the cytokine IL-13 revealed 14 variants with stimulation-dependent allelic expression patterns.
resultsOur approach discovered 96 allelic enhancer variants among all investigated cellular contexts, representing 32 independent AD risk loci. We discover a possible mechanistic role for activator protein 1 family transcription factors, as revealed by motif enrichment, genotype-dependent binding, and enhanced chromatin immunoprecipitation sequencing signal at AD risk variants with allelic enhancer activity compared with variants with nonallelic enhancer activity. We assign allelic enhancer variants to probable target genes, including previously identified risk genes such as KIF3A and FLG.
conclusionsOur systematic, genome-scale approach implicates causal genotype-dependent gene regulatory mechanisms for most AD risk loci, providing a unique resource for the discovery of the genetic mechanisms underlying this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.